These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533 [TBL] [Abstract][Full Text] [Related]
4. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374 [TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography scanning in malignant melanoma. Tyler DS; Onaitis M; Kherani A; Hata A; Nicholson E; Keogan M; Fisher S; Coleman E; Seigler HF Cancer; 2000 Sep; 89(5):1019-25. PubMed ID: 10964332 [TBL] [Abstract][Full Text] [Related]
6. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159 [TBL] [Abstract][Full Text] [Related]
7. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Kumar R; Alavi A Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921 [TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose-PET in the management of malignant melanoma. Kumar R; Mavi A; Bural G; Alavi A Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645 [TBL] [Abstract][Full Text] [Related]
9. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150 [TBL] [Abstract][Full Text] [Related]
10. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538 [TBL] [Abstract][Full Text] [Related]
11. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Rinne D; Baum RP; Hör G; Kaufmann R Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889 [TBL] [Abstract][Full Text] [Related]
13. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. Acland KM; O'Doherty MJ; Russell-Jones R J Am Acad Dermatol; 2000 Apr; 42(4):606-11. PubMed ID: 10727305 [TBL] [Abstract][Full Text] [Related]
14. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Gulec SA; Faries MB; Lee CC; Kirgan D; Glass C; Morton DL; Essner R Clin Nucl Med; 2003 Dec; 28(12):961-5. PubMed ID: 14663316 [TBL] [Abstract][Full Text] [Related]
15. FDG PET in early stage cutaneous malignant melanoma. McIvor J; Siew T; Campbell A; McCarthy M J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243 [TBL] [Abstract][Full Text] [Related]
16. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387 [TBL] [Abstract][Full Text] [Related]
17. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Clark PB; Soo V; Kraas J; Shen P; Levine EA Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694 [TBL] [Abstract][Full Text] [Related]
18. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. Gritters LS; Francis IR; Zasadny KR; Wahl RL J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058 [TBL] [Abstract][Full Text] [Related]
19. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Horn J; Lock-Andersen J; Sjøstrand H; Loft A Eur J Nucl Med Mol Imaging; 2006 Aug; 33(8):887-92. PubMed ID: 16586078 [TBL] [Abstract][Full Text] [Related]
20. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk]. Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765 [No Abstract] [Full Text] [Related] [Next] [New Search]